In a nutshell This trial determined whether pembrolizumab (Keytruda) is more effective at treating advanced NSCLC than chemotherapy in patients with high levels of a specific protein called PD-L1. The authors concluded that, for this subgroup of patients, pembrolizumab was more effective and safer than chemotherapy. Some background In some...
Read MoreIn a nutshell This review focused on whether adoptive immunotherapy (AI) can positively influence the chance of survival for patients with non-small-cell lunger cancer (NSCLC) that have undergone surgery. The authors concluded that AI post surgery is safe and effective. Some background For patients with NSCLC, surgery is usually followed by...
Read More
Transcript Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. Janet...
Read More
Transcript Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. Janet...
Read More
In a nutshell This trial examined whether osimertinib (Tagrisso) was effective at treating patients with advanced non-small cell lung cancer (NSCLC) that has progressed after EGFR tyrosine-kinase inhibitor (TKI) treatment. The authors concluded that osimertinib is both effective and tolerable as treatment for these patients. Some background...
Read More
In a nutshell This trial determined whether combining chemotherapy and immunotherapy would be beneficial for patients with advanced non-small-cell lung cancer (NSCLC). The authors concluded that a combination of chemotherapy agents, carboplatin (Paraplatin) and pemetrexed (Alimta), with the immunotherapy agent pembrolizumab (Keytruda) was tolerable and...
Read More
In a nutshell This study examined the risk of recurrence following early-stage non-small cell lung cancer (NSCLC) treated with surgery. The authors showed that the risk of relapse after surgery changes in a predictable way over time, where the first two years after surgery has the highest risk of relapse. They noted that the risk then declines but...
Read More
In a nutshell This trial examined whether bevacizumab (Avastin) is a safe and effective drug for treating patients with advanced NSCLC. The authors concluded that despite varying treatment lengths and dosage, the use of bevacizumab results in an increased overall survival. Some background Bevacizumab is an anti-cancer treatment that blocks the...
Read More
The northern hemisphere is experiencing all that autumn brings–colors in reds, golds, purples, browns and orange. Leaves, squash, corn, potatoes and pumpkins are the flowers of fall. Potatoes, first cultivated by the Incas, are now one of the largest food crops worldwide. To celebrate autumn we are sharing another recipe by Holly Clegg called...
Read More
In a nutshell This analysis examined whether tumor vaccines or cellular immunotherapies were more effective at treating non-small-cell lung cancer (NSCLC). They concluded that while both improved survival rates, cellular therapy was more effective. Some background Current research on the treatment of NSCLC is focused on both immunotherapy...
Read More
In a nutshell The authors aimed to summarize the results of two clinical trials to determine the effectiveness of alectinib as treatment for ALK-mutation positive NSCLC that has progressed beyond crizotinib. They concluded that alectinib is a suitable drug to treat this patient population. This treatment was FDA approved in 2015. Some...
Read More
In a nutshell The authors compared the effectiveness of different chemotherapy agents in combination with radiation. They stated that a combination of etoposide (Etopophos) and cisplatin (Platinol) was more effective then docetaxel (Taxotere) and cisplatin when combined with radiation therapy. Some background...
Read More
